Overview
flowchart TD
companies_ad_calcium_channel_h["Alzheimers Disease Calcium Channel and Homeosta"]
style companies_ad_calcium_channel_h fill:#4fc3f7,stroke:#333,color:#000
companies_ad_calcium_0["Scientific Rationale"]
companies_ad_calcium_channel_h -->|"includes"| companies_ad_calcium_0
style companies_ad_calcium_0 fill:#81c784,stroke:#333,color:#000
companies_ad_calcium_1["Calcium Dysregulation in AD"]
companies_ad_calcium_channel_h -->|"includes"| companies_ad_calcium_1
style companies_ad_calcium_1 fill:#ef5350,stroke:#333,color:#000
companies_ad_calcium_2["Therapeutic Approaches"]
companies_ad_calcium_channel_h -->|"includes"| companies_ad_calcium_2
style companies_ad_calcium_2 fill:#ffd54f,stroke:#333,color:#000
companies_ad_calcium_3["Calcium-Sensing Receptor CaSR"]
companies_ad_calcium_channel_h -->|"includes"| companies_ad_calcium_3
style companies_ad_calcium_3 fill:#ce93d8,stroke:#333,color:#000
companies_ad_calcium_4["Store-Operated Calcium Entry SOCE"]
companies_ad_calcium_channel_h -->|"includes"| companies_ad_calcium_4
style companies_ad_calcium_4 fill:#4fc3f7,stroke:#333,color:#000
companies_ad_calcium_5["Key Companies"]
companies_ad_calcium_channel_h -->|"includes"| companies_ad_calcium_5
style companies_ad_calcium_5 fill:#81c784,stroke:#333,color:#000
...
Overview
Mermaid diagram (expand to render)
This category page covers biotechnology and pharmaceutical companies developing calcium channel modulators and calcium homeostasis therapies for Alzheimer's disease (AD). Calcium dysregulation is a central pathological feature of AD, with impaired calcium signaling contributing to:
- Synaptic dysfunction and memory impairment
- Excitotoxicity through overactivation of NMDA receptors
- Tau phosphorylation via calcium-dependent kinases
- Neuroinflammation from calcium-activated microglia
- Mitochondrial dysfunction and energy failure
- Neuronal death through apoptotic pathways
Companies in this space target multiple mechanisms to restore calcium homeostasis:
- L-type calcium channels (Cav1.2, Cav1.3) — neuronal survival and gene expression
- T-type calcium channels (Cav3.1, Cav3.2, Cav3.3) — neuronal excitability and thalamocortical rhythms
- N-type calcium channels (Cav2.2) — neurotransmitter release
- P/Q-type calcium channels (Cav2.1) — synaptic transmission
- Store-operated calcium entry (SOCE) — calcium influx via Orai/STIM channels
- Calcium-sensing receptor (CaSR) — G-protein coupled calcium sensing
Scientific Rationale
Calcium Dysregulation in AD
Calcium homeostasis is disrupted in AD through multiple mechanisms:
Amyloid-beta effects: Aβ forms calcium-permeable ion channels in membranes
Presenilin mutations: Gamma-secretase mutations alter ER calcium release
NMDA receptor overactivation: Leads to calcium overload and excitotoxicity
Mitochondrial calcium buffering failure: Contributes to energy depletion
SOCE impairment: Store-operated calcium entry is disrupted in neurons[@calciumpd2023]Therapeutic Approaches
| Mechanism | Target | Therapeutic Goal | Development Stage |
|-----------|--------|------------------|-------------------|
| L-type modulators | Cav1.2/1.3 | Neuroprotection, improved cerebral blood flow | Phase 2 |
| T-type modulators | Cav3.1/3.2/3.3 | Reduce neuronal hyperexcitability | Preclinical |
| N-type blockers | Cav2.2 | Reduce excitatory neurotransmitter release | Phase 2 |
| CaSR agonists | CaSR | Activate neuroprotective signaling | Preclinical |
| SOCE modulators | Orai/STIM | Restore calcium influx | Discovery |
Calcium-Sensing Receptor (CaSR)
The CaSR is a Class C GPCR that senses extracellular calcium levels. In the brain, CaSR activation:
- Modulates neurotransmitter release
- Regulates neuronal excitability
- Promotes neuroprotection via MAPK signaling
- May reduce amyloid-beta toxicity[@casr2019]
Store-Operated Calcium Entry (SOCE)
SOCE is the primary mechanism for calcium influx in non-excitable cells and modulates neuronal calcium signaling. Key components:
- STIM1/2: ER calcium sensors
- Orai1/2/3: Plasma membrane calcium channels
Dysregulation of SOCE contributes to neurodegeneration, making it a promising therapeutic target[@soce2018].
Key Companies
L-Type Calcium Channel Modulators
Avanashi Brands
- Headquarters: San Francisco, California, USA
- Focus: Novel L-type calcium channel modulators for CNS disorders
- Lead Programs:
- AVA-301: Cav1.2 modulator for AD, preclinical
- Technology: Structure-based drug design platform
- Scientific Rationale: Cav1.3 channels are highly expressed in hippocampal neurons; modulation may protect against Aβ-induced toxicity
- Relevance: Addresses calcium dysregulation while maintaining neuroprotective signaling
MeditiC Pharma
- Headquarters: Boston, Massachusetts, USA
- Focus: Calcium homeostasis restoration therapies
- Lead Programs:
- MTX-101: Cav1.x targeting compound for AD, discovery
- Technology: Calcium signaling expertise platform
- Relevance: Novel approach targeting multiple calcium channels
Daiichi Sankyo Co., Ltd.
- Headquarters: Tokyo, Japan
- Ticker: TYO: 4568
- Focus: α2δ subunit calcium channel modulators
- Marketed Products:
- Tarlige (mirogabalin): α2δ calcium channel blocker approved for neuropathic pain
- Pipeline:
| Drug | Target | Indication | Stage |
|------|-------|------------|-------|
| Mirogabalin | α2δ calcium channel | Neuropathic pain | Approved |
| DA-9801 | Novel Ca2+ pathway | Alzheimer's disease | Preclinical |
- Technology: Established calcium channel modulation platform
- Relevance: Mirogabalin's mechanism may be applicable to calcium dysregulation in AD
- See: [Daiichi Sankyo](/companies/daiichi-sankyo)
Eli Lilly and Company
- Headquarters: Indianapolis, Indiana, USA
- Ticker: NYSE: LLY
- Focus: L-type calcium channel modulation in CNS disorders
- Pipeline: Early-stage programs targeting Cav1.x channels for AD
- Relevance: Large pharma resources for clinical development
- See: [Eli Lilly](/companies/eli-lilly)
AbbVie Inc.
- Headquarters: North Chicago, Illinois, USA
- Ticker: NYSE: ABBV
- Focus: Calcium channel modulators for neurodegenerative diseases
- Pipeline: Cav1.x modulators in early development
- See: [AbbVie](/companies/abbvie)
T-Type Calcium Channel Modulators
Accerise Inc.
- Headquarters: Tokyo, Japan
- Founded: 2016
- Focus: Structure-based drug design for CNS disorders, T-type calcium channel modulators
- Lead Programs:
- ACC-004: T-type and L-type calcium channel modulator for PD/AD
- Pipeline:
| Drug | Target | Indication | Stage |
|------|-------|------------|-------|
| ACC-004 | T-type/L-type calcium channels | Alzheimer's disease | Discovery |
| ACC-002 | LRRK2 | Parkinson's disease | Discovery |
- Technology: Proprietary structure-based drug design platform with cryo-EM
- Scientific Rationale: T-type channels (Cav3.1, Cav3.2) contribute to neuronal hyperexcitability and thalamocortical dysregulation in AD[@cav12018]
- See: [Accerise Inc.](/companies/accerrise)
Potassium-Activated Calcium Channels (CaSR)
Anavex Life Sciences Corp.
- Headquarters: New York, USA
- Ticker: NASDAQ: AVXL
- Focus: Sigma-1 receptor and calcium signaling modulators
- Lead Programs:
- Anavex 2-73 (blarcamesine): Sigma-1 receptor agonist, Phase 2/3 for AD
- Anavex 1-41: Sigma-1 receptor agonist, Phase 1
- Pipeline:
| Drug | Mechanism | Indication | Stage |
|------|-----------|------------|-------|
| Blarcamesine | Sigma-1 agonist | Alzheimer's disease | Phase 2/3 |
| Anavex 1-41 | Sigma-1 agonist | Alzheimer's disease | Phase 1 |
| Anavex 2-73 | Sigma-1 agonist | Parkinson's disease | Phase 2 |
- Technology: Sigma-1 receptor modulates calcium homeostasis and ER stress
- Mechanism: Sigma-1 receptor activation restores calcium signaling, reduces ER stress, and provides neuroprotection
- Relevance: Addresses calcium dysregulation through sigma-1 pathway
- See: [Anavex Life Sciences](/companies/anavex-life-sciences)
SOCE and Calcium Entry Modulators
Cerevel Therapeutics
- Headquarters: Boston, Massachusetts, USA
- Ticker: NASDAQ: CREV
- Focus: Multiple ion channel targets including calcium homeostasis
- Lead Programs:
- CVL-231: Kv7.2/7.3 opener, Phase 2 for AD
- CVL-234: Cav1.x modulator, discovery
- Pipeline:
| Drug | Mechanism | Indication | Stage |
|------|-----------|------------|-------|
| CVL-231 | Kv7.2/7.3 opener | Alzheimer's disease | Phase 2 |
| CVL-234 | Cav1.x modulator | Alzheimer's disease | Discovery |
- Technology: Formerly part of Pfizer, spun out 2020
- Relevance: Multi-target approach to calcium and potassium channel modulation
- See: [Cerevel Therapeutics](/companies/cerevel-therapeutics)
Kv7 Potassium and Calcium Modulation
Biohaven Pharmaceutical Holding Company Ltd.
- Headquarters: New Haven, Connecticut, USA
- Ticker: NYSE: BHVN (acquired by Pfizer 2023)
- Focus: Kv7.2/7.3 (KCNQ2/3) potassium channel activators
- Lead Programs:
- Troriluzole (BHVN-4151): Kv7 activator in Phase 2 for AD
- BHVN-7010: Next-generation Kv7 activator, Phase 1
- Pipeline:
| Drug | Mechanism | Indication | Stage |
|------|-----------|------------|-------|
| Troriluzole | Kv7.2/7.3 activator | Alzheimer's disease | Phase 2 |
| BHVN-7010 | Kv7 activator | Alzheimer's disease | Phase 1 |
| Troriluzole | Kv7.2/7.3 activator | ALS | Phase 3 |
- Technology: Acquired Kv7 platform from Bristol-Myers Squibb (2018)
- Relevance: Kv7 activation indirectly modulates calcium by stabilizing neuronal membrane potential
- See: [Biohaven](/companies/biohaven)
Pfizer Inc.
- Headquarters: New York, New York, USA
- Ticker: NYSE: PFE
- Focus: Calcium channel programs through Biohaven acquisition
- Pipeline: Continuation of Biohaven Kv7 programs for AD
- Relevance: Large pharma resources for late-stage clinical development
- See: [Pfizer](/companies/pfizer)
Competitive Landscape
| Company | Primary Mechanism | AD Focus | Key Asset | Stage |
|---------|-------------------|----------|-----------|-------|
| Avanashi | L-type Ca2+ channel | Yes | AVA-301 | Preclinical |
| MeditiC | Ca2+ homeostasis | Yes | MTX-101 | Discovery |
| Daiichi Sankyo | α2δ Ca2+ channel | Yes | Mirogabalin (repurposing) | Approved |
| Eli Lilly | L-type Ca2+ channel | Emerging | Pipeline | Discovery |
| AbbVie | L-type Ca2+ channel | Emerging | Pipeline | Discovery |
| Accerise | T-type/L-type Ca2+ | Yes | ACC-004 | Discovery |
| Anavex | Sigma-1/Ca2+ | Yes | Blarcamesine | Phase 2/3 |
| Cerevel | Cav1.x/Kv7 | Yes | CVL-234 | Discovery |
| Biohaven | Kv7/Ca2+ | Yes | Troriluzole | Phase 2 |
| Pfizer | Kv7 (via Biohaven) | Yes | Troriluzole | Phase 2 |
Therapeutic Potential in AD
Disease-Modifying Mechanisms
Neuroprotection: L-type and T-type channel modulation protects neurons from Aβ toxicity
Excitotoxicity reduction: Calcium channel blockade reduces glutamate-induced cell death
Synaptic preservation: Restoring calcium homeostasis maintains synaptic function
Mitochondrial protection: Normal calcium levels prevent mitochondrial dysfunction
Anti-inflammatory effects: Calcium modulation reduces microglial activationClinical Development Considerations
- Biomarker strategies: Calcium imaging, EEG, synaptic markers for patient selection
- Combination approaches: Calcium modulators combined with amyloid/tau-targeting therapies
- Genetic stratification: Targeting patients with calcium channel genetic variants
- Safety concerns: Calcium channel modulators require careful dosing to avoid cardiac effects
Cross-References
- [Alzheimer's Disease - Therapeutic Approaches](/diseases/alzheimers-disease)
- [Calcium Dysregulation Pathway](/mechanisms/calcium-dysregulation-pathway)
- [L-type Calcium Channels](/proteins/l-type-ca)
- [T-type Calcium Channels](/proteins/cacna1g-protein)
- [Calcium Signaling in Neurodegeneration](/therapeutics/calcium-homeostasis-modulators)
- [Sigma-1 Receptor in AD](/proteins/sigma1-receptor-protein)
- [Ion Channel Modulators Overview](/companies/ad-ion-channel-modulator-companies)
External Links
- [PubMed - Calcium Channel Modulators in AD](https://pubmed.ncbi.nlm.nih.gov/?term=Alzheimer+calcium+channel+modulators)
- [PubMed - CaSR in Neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/31619947/)
- [PubMed - SOCE in Neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/29573012/)
- [ClinicalTrials.gov - Calcium AD](https://clinicaltrials.gov/search?cond=Alzheimer+disease&intr=calcium+channel)
References
[Avanashi Brands](https://avanashibrands.com) (n.d.)
[MeditiC Pharma](https://mediticpharma.com) (n.d.)
[Cerevel Therapeutics](https://www.cerevel.com) (n.d.)
[Biohaven Pharmaceutical Holding Company Ltd.](https://www.biohaven.com) (n.d.)
[Daiichi Sankyo Co., Ltd.](https://www.daiichisankyo.com) (n.d.)
[Accerise Inc.](https://www.accerse.co.jp) (n.d.)
[Anavex Life Sciences Corp.](https://www.anavex.com) (n.d.)
[AbbVie Inc.](https://www.abbvie.com) (n.d.)
[Eli Lilly and Company](https://www.lilly.com) (n.d.)
[Pfizer Inc.](https://www.pfizer.com) (n.d.)
[Chan CS et al, Calcium, mitochondria, and the pathophysiology of Parkinson's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37855612/)
[Kim HL et al, Calcium-sensing receptor as a therapeutic target for neurodegenerative diseases (2019)](https://pubmed.ncbi.nlm.nih.gov/31619947/)
[Moccia F et al, Store-operated calcium entry in neurodegenerative diseases (2018)](https://pubmed.ncbi.nlm.nih.gov/29573012/)
[Ortner NJ, Striessnig J, Voltage-gated calcium channels as drug targets (2018)](https://pubmed.ncbi.nlm.nih.gov/29486583/)